Literature DB >> 10068583

Transmission dynamics of epidemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in England and Wales.

D J Austin1, R M Anderson.   

Abstract

A simple epidemiological framework for the analysis of the transmission dynamics of hospital outbreaks of epidemic methicillin-resistant Staphylococcus aureus (EMRSA) and vancomycin-resistant enterococci (VRE) in hospitals in England and Wales is presented. Epidemic strains EMRSA-15 and EMRSA-16 are becoming endemic in hospitals in the United Kingdom, and theory predicts that EMRSA-15 and EMRSA-16 will reach respective endemic levels of 158 (95% confidence interval [CI], 143-173) and 116 (95% CI, 109-123) affected hospitals with stochastic fluctuations of up to 30 hospitals in each case. An epidemic of VRE is still at an early stage, and the incidence of hospitals newly affected by VRE is growing exponentially at a rate r=0.51/year (95% CI, 0.48-0.54). The likely impact of introducing surveillance policies if action is taken sufficiently early is estimated. Finally, the role of heterogeneity in hospital size is considered: "Super-spreader hospitals" may increase transmission by 40%-132% above the expected mean.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068583     DOI: 10.1086/314682

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

Review 2.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: resistance is a regional problem.

Authors:  David L Smith; Jonathan Dushoff; Eli N Perencevich; Anthony D Harris; Simon A Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-25       Impact factor: 11.205

4.  Screening strategies in surveillance and control of methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  J V Robotham; D R Jenkins; G F Medley
Journal:  Epidemiol Infect       Date:  2006-07-13       Impact factor: 2.451

5.  Efficient surveillance for healthcare-associated infections spreading between hospitals.

Authors:  Mariano Ciccolini; Tjibbe Donker; Hajo Grundmann; Marc J M Bonten; Mark E J Woolhouse
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

6.  Pharmacokinetics of a new parenteral oligosaccharide antibiotic, SCH27899 (Ziracin), in healthy subjects.

Authors:  O Kozawa; T Uematsu; H Matsuno; M Niwa; K Kohno; A Kawato; K Takahashi; S Nagashima; M Kanamaru
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital.

Authors:  I Björholt; E Haglind
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

8.  Peripatetic health-care workers as potential superspreaders.

Authors:  Laura Temime; Lulla Opatowski; Yohan Pannet; Christian Brun-Buisson; Pierre Yves Boëlle; Didier Guillemot
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

9.  A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future.

Authors:  Bruce R Levin; Fernando Baquero; Pål J Johnsen
Journal:  Curr Opin Microbiol       Date:  2014-07-11       Impact factor: 7.934

10.  What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?

Authors:  Caroline Colijn; Ted Cohen; Christophe Fraser; William Hanage; Edward Goldstein; Noga Givon-Lavi; Ron Dagan; Marc Lipsitch
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.